BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 30340072)

  • 21. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Peripheral blood CD4⁺;CXCR5⁺; follicular helper T cells are related to hyperglobulinemia of patients with chronic hepatitis B].
    Ma Z; Xie Y; Wang Y; Ma L; He Y; Zhang Y; Lian J; Guo Y; Jia Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 May; 29(5):515-8, 521. PubMed ID: 23643274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.
    Wang Z; Li X; Shi C; Zhang M; Chen R; Wu W; Hou Q; Ke W; Fan T; Wen Z; Hao X; Qu N
    Mol Med Rep; 2015 Jan; 11(1):427-33. PubMed ID: 25324041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Alterations of IFN-γ and IL-4 of peripheral blood T cells in patients with chronic HBV infection].
    Li M; Sun X; Zhou Z; Zhang X; Jin S; Gao Y; Gao Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Feb; 32(2):240-4. PubMed ID: 26927386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-33 Enhances Humoral Immunity Against Chronic HBV Infection Through Activating CD4(+)CXCR5(+) TFH Cells.
    Zhao PW; Shi X; Li C; Ayana DA; Niu JQ; Feng JY; Wang J; Jiang YF
    J Interferon Cytokine Res; 2015 Jun; 35(6):454-63. PubMed ID: 25714983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
    Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X
    J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequency of CD4+CXCR5+ TFH cells in patients with hepatitis b virus-associated membranous nephropathy.
    Liu Y; Zhao P; Qu Z; Ayana DA; Jiang Y
    Int Immunopharmacol; 2014 Sep; 22(1):98-106. PubMed ID: 24975830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating CXCR5
    Ekman I; Ihantola EL; Viisanen T; Rao DA; Näntö-Salonen K; Knip M; Veijola R; Toppari J; Ilonen J; Kinnunen T
    Diabetologia; 2019 Sep; 62(9):1681-1688. PubMed ID: 31270583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB.
    Yan W; Wu D; Wang X; Chen T; Lai Q; Zheng Q; Jiang J; Hou J; Han M; Ning Q
    Antivir Ther; 2015; 20(6):591-602. PubMed ID: 25814467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.
    Sonneveld MJ; Rijckborst V; Zeuzem S; Heathcote EJ; Simon K; Senturk H; Pas SD; Hansen BE; Janssen HL
    Hepatology; 2012 Jul; 56(1):67-75. PubMed ID: 22307831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.
    Gheorghiţa VI; Caruntu FA; Curescu M; Olaru I; Radu MN; Colţan G; Streinu-Cercel A
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):27-32. PubMed ID: 23539387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
    Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
    Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B virus-specific T-cell responses during IFN administration in a small cohort of chronic hepatitis B patients under nucleos(t)ide analogue treatment.
    Sprinzl MF; Russo C; Kittner J; Allgayer S; Grambihler A; Bartsch B; Weinmann A; Galle PR; Schuchmann M; Protzer U; Bauer T
    J Viral Hepat; 2014; 21(9):633-41. PubMed ID: 24251783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD56
    Shi A; Zhang X; Xiao F; Zhu L; Yan W; Han M; Luo X; Chen T; Ning Q
    J Viral Hepat; 2018 Nov; 25(11):1352-1362. PubMed ID: 29888839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical characteristics of chronic hepatitis B cured by peginterferon in combination with nucleotide analogs.
    Bao X; Guo J; Xiong F; Qu Y; Gao Y; Gu N; Lu J
    Int J Infect Dis; 2020 Jul; 96():562-566. PubMed ID: 32474201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study on the distribution of CD8+ memory T cell subsets and IFN-γ level during the spontaneous clearance of hepatitis B virus in patients with chronic hepatitis B virus infection.
    Ma XJ; Chen XF; Chen WL; Chen R; Huang J; Luo XD; Liao JY; Chen XP
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4675-4679. PubMed ID: 29131246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
    Brunetto MR; Moriconi F; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Luo K; Wang Y; Hadziyannis S; Wolf E; McCloud P; Batrla R; Marcellin P
    Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantification of HBsAg and HBV-DNA during therapy with peginterferon alpha-2b plus lamivudine and peginterferon alpha-2b alone in a German chronic hepatitis B cohort.
    Wiegand J; Brosteanu O; Kullig U; Wiese M; Berr F; Maier M; Tillmann HL; Schiefke I
    Z Gastroenterol; 2011 Nov; 49(11):1463-9. PubMed ID: 22069045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis.
    Penna A; Laccabue D; Libri I; Giuberti T; Schivazappa S; Alfieri A; Mori C; Canetti D; Lampertico P; Viganò M; Colombo M; Loggi E; Missale G; Ferrari C
    J Hepatol; 2012 Jun; 56(6):1239-46. PubMed ID: 22326467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.